Should all patients with metabolic syndrome be treated with statins?

Nicola Abate, Manisha Chandalia

Research output: Contribution to journalReview articlepeer-review


The metabolic syndrome is a constellation of cardiovascular risk factors that include atherogenic dyslipidemia, elevated blood pressure, abdominal/truncal obesity, and glucose intolerance. Current National Cholesterol Education Program (NCEP) recommendations for specific treatment of the metabolic syndrome are centered on therapeutic lifestyle changes. A recent publication from the NCEP Adult Treatment Panel III suggests pharmacologic intervention for parameters of metabolic syndrome, including dyslipidemia, hypertension, and hyperglycemia, to prevent cardiovascular disease, based on risk category. This review looks at the clinical trial evidence to support the use of statins in metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)72-76
Number of pages5
JournalCurrent Diabetes Reports
Issue number1
StatePublished - Feb 1 2006

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Should all patients with metabolic syndrome be treated with statins?'. Together they form a unique fingerprint.

Cite this